Please assess the completion status of the following clinical trial:

Trial Title: Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological confirmation of non-small cell lung cancer~2. Patients who have been treated in the past with stereotactic radiosurgery, stereotactic radiotherapy, GliaSite or surgical resection will be allowed to enroll in this study~3. A diagnostic contrast-enhanced MRI or CT scan must be performed, demonstrating brain metastases~4. Age 18-70~5. Patients must have KPS \>/= 70~6. Patients cannot be treated on any other treatment related protocols within 30 days prior to study entry or during participation in the study~7. No uncontrolled or symptomatic major medical illnesses or psychiatric impairments, such as Alzheimer's or schizophrenia~8. Screening Clinical Laboratory Values: ANC \>1500/ul, Platelets \>80,000/ul, baseline AST and/or ALT within normal limits (within 30 days of starting protocol treatment)~9. All women of childbearing potential (A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months \[i.e., who has had menses at any time in the preceding 24 consecutive months\]) and male participants must practice effective contraception (abstinence, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study.~10. Continued from #10: All women of child-bearing potential must have a negative serum pregnancy test and practice birth control while on study.~11. Patients must provide verbal and written informed consent to participate in the study.~Exclusion Criteria:~1. Prior cranial radiation therapy, other than stereotactic radiosurgery, Stereotactic Radiotherapy or GliaSite.~2. Patients with known Acquired Immune Deficiency (AIDS), as regimens with tyrosine kinase inhibitors may pose a safety risk related to excess toxicity or interference with anti-viral effectiveness~3. Women who are pregnant or lactating, due to possible adverse effects on the developing fetus or infant due to study drug~4. Patients with active connective tissue disorders, such as lupus or scleroderma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tarceva + RT (Type: EXPERIMENTAL): Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).